New strategies in the development of anti-atherosclerotic drugs
Related Experiment Videos
Abstract:
The results of several recently completed trials of cardiovascular prevention, by the use of hypolipidemic or anti-platelet compounds, have suggested that new strategies be followed for the development of anti-atherosclerotic drugs. The final outcome of preventive studies with hypolipidemic compounds is markedly influenced by the significance of the achieve hypolipidemia, as well as by the side-effects, some which, i.e. lithogenicity, may be related to the drugs' mechanism of action. Significant differences may, moreover, exist between the findings in animal models and in humans, particularly by clofibrate and related compounds. The evaluation of drugs active on lipoprotein biosynthesis in the gut (metformin), potent enzyme inhibitors (compactin) and with chelating activity (cetaben), is awaited with interest. In the field of drugs affected platelets, a selective sensitivity for the major compounds in different vascular areas has been observed. Aspirin appears to be mostly effective in cerebro-vascular prevention. Agents affecting the thrombin-platelet coagulation interaction, i.e. GYKI 14,451, may offer an interesting opportunity for testing the importance of this pathway in clinical thrombosis.
Insights
New cardiovascular prevention strategies are needed, focusing on anti-atherosclerotic drugs. Research highlights the importance of achieving hypolipidemia and managing side effects, with varied results between animal models and humans.
Area of Science:
- Cardiovascular disease research
- Pharmacology
- Atherosclerosis drug development
Background:
- Recent trials suggest new strategies for anti-atherosclerotic drug development.
- Hypolipidemic and anti-platelet compounds are key areas of focus.
Purpose of the Study:
- To review current findings in cardiovascular prevention trials.
- To identify promising avenues for future anti-atherosclerotic drug development.
Main Methods:
- Analysis of outcomes from cardiovascular prevention trials.
- Evaluation of hypolipidemic and anti-platelet compounds.
- Comparison of animal model and human study findings.
Main Results:
- Hypolipidemic drug efficacy depends on achieving lipid reduction and managing side effects like lithogenicity.
- Differences exist between animal and human responses to certain compounds (e.g., clofibrate).
- Aspirin shows effectiveness in cerebrovascular prevention; thrombin-platelet interaction inhibitors warrant further investigation.
Conclusions:
- Future anti-atherosclerotic drug development requires novel strategies beyond current hypolipidemic and anti-platelet approaches.
- Further research is needed on drugs targeting lipoprotein biosynthesis, enzyme inhibition, chelation, and thrombin-platelet pathways.